Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)
CUSIP: 89532M101
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 143,562,667
- Total 13F shares
- 79,496,969
- Share change
- +19,459,346
- Total reported value
- $329,526,035
- Put/Call ratio
- 84%
- Price per share
- $4.12
- Number of holders
- 109
- Value change
- +$80,359,022
- Number of buys
- 67
- Number of sells
- 29
Quarterly Holders Quick Answers
What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89532M101:
Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| NEA Management Company, LLC |
13F
|
Company |
7.9%
|
11,370,376
|
$37,977,056 | — | 30 Sep 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
5.1%
|
7,381,090
|
$24,652,841 | — | 30 Sep 2024 | |
| Rubric Capital Management LP |
13F
|
Company |
3.5%
|
5,026,931
|
$16,789,950 | — | 30 Sep 2024 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
3.1%
|
4,400,000
|
$14,696,000 | — | 30 Sep 2024 | |
| VR Adviser, LLC |
13F
|
Company |
2.4%
|
3,422,656
|
$11,431,671 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.3%
|
3,262,381
|
$10,896,353 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2.2%
|
3,221,752
|
$10,760,651 | — | 30 Sep 2024 | |
| Logos Global Management LP |
13F
|
Company |
1.9%
|
2,750,000
|
$9,185,000 | — | 30 Sep 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
1.8%
|
2,567,990
|
$8,577,087 | — | 30 Sep 2024 | |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
— |
1.4%
|
1,266,457
|
$8,042,002 | $0 | 31 Dec 2024 | |
| TPG GP A, LLC |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
3,824,883
|
$7,726,264 | — | 01 Jul 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
1.1%
|
1,612,903
|
$5,387,096 | — | 30 Sep 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.1%
|
1,538,517
|
$5,138,647 | — | 30 Sep 2024 | |
| MAI Capital Management |
13F
|
Company |
0.92%
|
1,327,285
|
$4,433,132 | — | 30 Sep 2024 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.92%
|
1,322,800
|
$4,418,152 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.88%
|
1,264,166
|
$4,222,647 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.66%
|
952,912
|
$3,182,726 | — | 30 Sep 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.52%
|
750,000
|
$2,505,000 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.42%
|
606,227
|
$2,024,798 | — | 30 Sep 2024 | |
| Peter W. Sonsini |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
3,948,948
mixed-class rows
|
$1,916,875 | — | 11 Apr 2022 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.34%
|
482,575
|
$1,611,801 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.3%
|
433,642
|
$1,448,364 | — | 30 Sep 2024 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.3%
|
424,725
|
$1,418,582 | — | 30 Sep 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.2%
|
290,500
|
$970,270 | — | 30 Sep 2024 | |
| Checkpoint Capital L.P. |
13F
|
Company |
0.17%
|
250,000
|
$835,000 | — | 30 Sep 2024 | |
| Tejara Capital Ltd |
13F
|
Company |
0.17%
|
241,613
|
$806,987 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.14%
|
198,480
|
$662,922 | — | 30 Sep 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.13%
|
185,481
|
$619,507 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
164,238
|
$548,555 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.11%
|
150,918
|
$504,066 | — | 30 Sep 2024 | |
| J. Goldman & Co LP |
13F
|
Company |
0.1%
|
148,917
|
$497,383 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.1%
|
137,284
|
$458,529 | — | 30 Sep 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.09%
|
122,447
|
$409,000 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.07%
|
100,517
|
$335,727 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.07%
|
96,350
|
$321,809 | — | 30 Sep 2024 | |
| RAYMOND JAMES & ASSOCIATES |
13F
|
Company |
0.07%
|
95,383
|
$318,579 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.07%
|
95,232
|
$318,075 | — | 30 Sep 2024 | |
| Shay Capital LLC |
13F
|
Company |
0.07%
|
93,962
|
$313,833 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.06%
|
81,971
|
$273,773 | — | 30 Sep 2024 | |
| OPPENHEIMER & CO INC |
13F
|
Company |
0.06%
|
81,947
|
$273,703 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.06%
|
81,124
|
$270,954 | — | 30 Sep 2024 | |
| PFS Partners, LLC |
13F
|
Company |
0.06%
|
79,000
|
$263,860 | — | 30 Sep 2024 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
76,544
|
$255,657 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.05%
|
72,210
|
$241,133 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.05%
|
70,700
|
$236,138 | — | 30 Sep 2024 | |
| WealthTrust Axiom LLC |
13F
|
Company |
0.04%
|
63,500
|
$212,090 | — | 30 Sep 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.04%
|
53,990
|
$180,327 | — | 30 Sep 2024 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.03%
|
50,000
|
$167,000 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.03%
|
49,881
|
$166,603 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
47,747
|
$159,475 | — | 30 Sep 2024 |
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q4 2024
As of 31 Dec 2024,
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
79,496,969 shares.
The largest 10 holders included
NEA Management Company, LLC, Frazier Life Sciences Management, L.P., VIKING GLOBAL INVESTORS LP, Rubric Capital Management LP, Point72 Asset Management, L.P., BlackRock, Inc., VANGUARD GROUP INC, Vivo Capital, LLC, Woodline Partners LP, and MPM BIOIMPACT LLC.
This page lists
109
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
92
Q4 2024 holders
109
Holder diff
17
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.